Guías clínicas 239 Guía AUGE MINSAL Virus Hepatitis C - A. Soza R. et al. confirmed results. Rev Med Chile 1996; 124: 615-6. 8.- Salud MD. Encuesta Nacional de Salud Chile 2003. Enfermedades transmisibles: prevalencia de virus de hepatitis, hantavirus y virus del papiloma humano. In; 2003. 9.- Encuesta Nacional de Salud ENS Chile 2009-2010. http:// web.minsal.cl/portal/url/item/ bcb03d7bc28b64dfe040010165012d23. pdf 2013;Accedido 20/12/2013. 10.- González R, Soza A, Hernández V, Pérez RM, Álvarez M, Morales A, et al. Incidence and prevalence of hepatitis C virus infection in Chile. Ann Hepatol 2005; 4: 127-30. 11.- Buckel E, Uribe M, Ferrario M, Godoy J, Cheng S, Brahm J, et al. Resultados en 165 trasplantes hepáticos consecutivos. La mayor experiencia en Chile. Gastroenterol Hepatol 2002; 25 (Supl 2): 37. 12.- Benítez C, Morales E, Pacheco F, Soza A, Jarufe N, Crovari F, et al. Trasplante hepático: Evolución de los resultados de un centro universitario. Gastroenterol Latinoam 2005; 16: 371. 13.- Hepp J, Ríos H, Suárez L, Zaror M, Quiroga M, Rodríguez G, et al. Liver transplantation in adults: a caseload from Clinica Alemana de Santiago, Chile. Rev Med Chile 2002; 130: 779-86. 14.- Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36: S35-46. 15.- Seeff LB, Hoofnagle JH. National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002. Hepatology 2002; 36: S1-2. 16.- Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology 2002; 36: S47-56. 17.- Wong JB. Cost-effectiveness of treatments for chronic hepatitis C. Am J Med 1999; 107: 74S-78S. 18.- Moyer VA, Force USPST. Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2013; 159: 349-57. 19.- Méndez-Sánchez N, Parana R, Cheinquer H, Alves de Mattos A, Gadano A, Silva M, et al. Latin american association for the study of the liver recommendations on treatment of hepatitis C. Ann Hepatol 2014; 13 Suppl 2: 1-66. 20.- Vrielink H, Reesink HW, van den Burg PJ, Zaaijer HL, Cuypers HT, Lelie PN, van der Poel CL. Performance of three generations of anti-hepatitis C virus enzyme-linked immunosorbent assays in donors and patients. Transfusion 1997; 37: 845-9. 21.- Colin C, Lanoir D, Touzet S, Meyaud-Kraemer L, Bailly F, Trepo C. Sensitivity and specificity of third-generation hepatitis C virus antibody detection assays: an analysis of the literature. J Viral Hepat 2001; 8: 87-95. 22.- Takaki A, Wiese M, Maertens G, Depla E, Seifert U, Liebetrau A, et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a singlesource outbreak of hepatitis C. Nat Med 2000; 6: 578-82. 23.- Chevaliez S, Pawlotsky JM. Interferonbased therapy of hepatitis C. Adv Drug Deliv Rev 2007; 59: 1222-41. 24.- Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Recomm Rep 1998; 47: 1-39. 25.- Bedogni G, Miglioli L, Masutti F, Ferri S, Castiglione A, Lenzi M, et al. Natural course of chronic HCV and HBV infection and role of alcohol in the general population: the Dionysos Study. Am J Gastroenterol 2008; 103: 2248-53. 26.- Lok AS, Seeff LB, Morgan TR, di Bisceglie AM, Sterling RK, Curto TM, et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 2009; 136: 138-48. 27.- Cheung O, Sanyal AJ. Hepatitis C infection and nonalcoholic fatty liver disease. Clin Liver Dis 2008; 12: 573-85, viii-ix. 28.- Vento S, Garofano T, Renzini C, Cainelli F, Casali F, Ghironzi G, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998; 338: 286-90. 29.- Sarrazin C, Kieffer TL, Bartels D, Hanzelka B, Muh U, Welker M, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007; 132: 1767-77. 30.- Bedossa P. Liver biopsy. Gastroenterol Clin Biol 2008; 32: 4-7. 31.- Myers RP, Fong A, Shaheen AA. Utilization rates, complications and costs of percutaneous liver biopsy: a population-based study including 4275 biopsies. Liver Int 2008; 28: 705-12. 32.- Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD, American Association for the Study of Liver D. Liver biopsy. Hepatology 2009; 49: 1017-44. 33.- Lin ZH, Xin YN, Dong QJ, Wang Q, Jiang XJ, Zhan SH, et al. Performance of the aspartate aminotransferase-toplatelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology 2011; 53: 726-36. 34.- Forns X, Ampurdanes S, Llovet JM, Aponte J, Quinto L, Martínez-Bauer E, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002; 36: 986-92. 35.- Poynard T, Imbert-Bismut F, Munteanu M, Messous D, Myers RP, Thabut D, et al. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol 2004; 3: 8. 36.- Castera L. Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology 2012; 142: 1293-1302 e1294. 37.- Friedrich-Rust M, Ong MF, Martens S, Sarrazin C, Bojunga J, Zeuzem S, Herrmann E. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 2008; 134: 960-74. 38.- Castera L. Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis. J Viral Hepat 2009; 16: 300-14. Gastroenterol. latinoam 2015; Vol 26, Nº 4: 214-247
gastrolat2015n400006
To see the actual publication please follow the link above